| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -61,040 | -38,916 |
| Purchases of investments | 148,592 | - |
| Payment of security deposit | 59 | - |
| Purchases of property and equipment | 193 | 136 |
| Net cash used in investing activities | -148,844 | -136 |
| Proceeds from the pre-closing financing, net of 14,548 of offering costs | 190,452 | 190,452 |
| Cash acquired in connection with the reverse recapitalization | 156 | 156 |
| Net cash provided by financing activities | 190,608 | 190,608 |
| Effect on exchange rates on cash and cash equivalents | -4 | - |
| Net (decrease) increase in cash and cash equivalents | -19,280 | 151,556 |
| Cash and cash equivalents at beginning of period | 69,386 | - |
| Cash and cash equivalents at end of period | 50,106 | - |
Jade Biosciences, Inc. (JBIO)
Jade Biosciences, Inc. (JBIO)